Today, DMT-based psychedelic therapeutic products offer an interesting avenue for researchers to explore in the treatment of addiction and substance use disorders. It’s actually been proposed that DMT can increase the brain’s neuro-plasticity and even promote the formation of new neural connections, or synapses.
It’s a big-ticket business with billions in annual revenues pouring in, yet it’s also very personal for so many patients: drug addiction recovery is a major challenge in North America and worldwide, with numerous costs for society and opportunities for ambitious clinicians, researchers, and companies that develop patents for novel treatments.
It’s becoming increasingly clear that there’s a critical lack of safe, effective, proven and widely available treatment options for opioid addiction. Therapy and 12-step programs can help some people, but they’re just not enough for many patients who struggle with opioid addiction today.
Just a few years ago, cannabis was considered the “final frontier” of decriminalization. The progress in this area was swift and sweeping, but as it turns out cannabis legalization was just the beginning. The real final frontier is psychedelic drugs, and the regulatory barriers are being broken down one by one.
There’s a reason principals of Wealth Research Group have invested nearly half a million dollars in PlantX.com (US: PLTXF); we consider it to be a sort of ETF for the plant-based sales growth, happening globally.
In 2020, plant-based and vegan products have seen over a 100% sales increase. There are very few industries this year, which have experienced a positive improvement and progress like this one has.